A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group
L Eidenschink Brodersen, TA Alonzo, AJ Menssen… - Leukemia, 2016 - nature.com
3 Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell
molecular signature. Science 2002; 298: 601-604. 4 Wang J, Sun Q, Morita Y, Jiang H …
molecular signature. Science 2002; 298: 601-604. 4 Wang J, Sun Q, Morita Y, Jiang H …
Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group
FM Uckun, HN Sather, PS Gaynon… - Blood, The Journal …, 1997 - ashpublications.org
Leukemic cells from a significant number of children with acute lymphoblastic leukemia
(ALL) express protein antigens characteristic of both lymphoid and myeloid cells, yet the …
(ALL) express protein antigens characteristic of both lymphoid and myeloid cells, yet the …
Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy
CH Pui, FG Behm, B Singh, GK Rivera, MJ Schell… - 1990 - ashpublications.org
Frequency and clinical significance of myeloid-associated antigen expression in blast cells
were assessed in 372 consecutive children with acute lymphoblastic leukemia (ALL). A …
were assessed in 372 consecutive children with acute lymphoblastic leukemia (ALL). A …
Integrative genomic analysis of pediatric myeloid-related acute leukemias identifies novel subtypes and prognostic indicators
Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to
the discovery of somatic mutations with prognostic implications. Although gene-expression …
the discovery of somatic mutations with prognostic implications. Although gene-expression …
Revised risk stratification criteria for children with newly diagnosed acute myeloid leukemia: a report from the Children's Oncology Group
TM Cooper, RE Ries, TA Alonzo, RB Gerbing… - Blood, 2017 - ashpublications.org
Introduction: Currently, most phenotypic, cytogenetic or molecular markers identified in
children with acute myeloid leukemia (AML) are not used for risk stratification or treatment …
children with acute myeloid leukemia (AML) are not used for risk stratification or treatment …
Deciphering the significance of CD56 expression in pediatric acute myeloid leukemia: a report from the Children's oncology group
Background In patients with acute myeloid leukemia (AML), CD56 expression has been
associated with adverse clinical outcome. We reported on a phenotype associated with very …
associated with adverse clinical outcome. We reported on a phenotype associated with very …
Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies
MC Putti, R Rondelli, MG Cocito, M Aricó… - Blood, The Journal …, 1998 - ashpublications.org
The importance of coexpression of myeloid antigens in childhood acute lymphoblastic
leukemia (ALL) has long been debated; results are conflicting. We studied children with ALL …
leukemia (ALL) has long been debated; results are conflicting. We studied children with ALL …
[HTML][HTML] Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol …
Diagnostic biomarkers can be used to determine relapse risk in acute myeloid leukemia,
and certain genetic aberrancies have prognostic relevance. A diagnostic immunophenotypic …
and certain genetic aberrancies have prognostic relevance. A diagnostic immunophenotypic …
Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia
H Matsuo, Y Iijima‐Yamashita, M Yamada… - Pediatrics …, 2018 - Wiley Online Library
Background In acute myeloid leukemia (AML), accurate detection of minimal residual
disease (MRD) enables better risk‐stratified therapy. There are few studies, however, on the …
disease (MRD) enables better risk‐stratified therapy. There are few studies, however, on the …
Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia
For the 365 children diagnosed with acute myeloid leukemia in the US annually, 5‐year
survival for patients on COG trials with low, intermediate, and high risk disease is 83%, 62 …
survival for patients on COG trials with low, intermediate, and high risk disease is 83%, 62 …